Indy Hematology Clinical Rounds®

A quarterly CME education program at Ruth’s Chris Steak House, Indianapolis

2727 E 86th St, Indianapolis, IN 46240

Held: January 21st, 2027

Discuss Hematologic Malignancies and Disorders

In pursuant of promoting education in hematologic malignancies and disorders, Dr. Ruemu Ejedafeta Birhiray, President and CEO of Indy Hematology Education, Inc, in collaboration with Dr’s. Sumeet Bhatia and Catherine Socec, co- chair “Indy Hematology Clinical Rounds®” a quarterly CME education program.

This program is to create a tumor board forum where management of complex hematological cases can be discussed amongst physicians practicing mainly hematology malignancies and disorders, so that consistency is achieved for better outcomes

Earn up to 2 CME Credits

Our Speaker

Dr. Rami Komrokji

Moffitt Cancer Center (Tampa, FL)

  • Vice Chair of the Malignant Hematology Department

  • Head of the Leukemia and MDS Section

Dr. Rami Komrokji is a senior Member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center, and Professor in Medicine & Oncologic Sciences at the College of Medicine, at the University of South Florida in Tampa, Florida.

After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.

Dr. Komrokji is an expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and for Pacritinib in myelofibrosis.

He has authored or co-authored more than 325 peer-reviewed manuscripts, 20 book chapters, and more than 700 abstracts in Hematologic Malignancies. He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and is currently a member of the NIH MDS natural history study steering committee and aplastic anemia and MDS foundation board of directors. He was member of the editorial board for Journal of Clinical Oncology (JCO). He is peer reviewer for several medical journals including Blood Journal, JCO and Leukemia Journal.

Dr. Komrokji’s research interests are in Phase I and II Clinical Trials, and in the outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Myeloid Leukemias, and Myeloproliferative neoplasms.

Our Speaker

Our Speaker

Our Sponsor